RxDoctor Payments Data

Angelo Chinnici, MD

Internal Medicine · Asbury Park, NJNPI 1417984659

Payments from drug & device makers

$43,899in general payments, 2019–2025

Across 720 payments — averaging $60.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$33K
  • AstraZeneca$2K
  • GSK$1K
  • AbbVie$1K
  • Gilead$796
  • Novo Nordisk$663
  • plus $5K from 38 others

What the payments were for

  • Speaking & faculty fees$29,05066%
  • Travel & lodging$2,2905%
  • Food & beverage$12,54029%
  • Education$180%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$43,899 in reported general payments places this provider in the 95th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$323,949
Medicare patients
508
Services billed
2,700

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide224$234,169
Repatha SureclickEvolocumab170$125,331
Trelegy ElliptaFluticasone/Umeclidin/Vilanter98$69,825
FarxigaDapagliflozin Propanediol77$66,355
EliquisApixaban86$66,136
BiktarvyBictegrav/Emtricit/Tenofov Ala14$60,309
JanuviaSitagliptin Phosphate39$40,057
UbrelvyUbrogepant14$34,774
ProliaDenosumab19$32,558
JanumetSitagliptin Phos/Metformin Hcl23$20,849
XareltoRivaroxaban27$20,569
VraylarCariprazine Hcl13$16,985
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl92$15,619
TradjentaLinagliptin17$14,677
Breztri AerosphereBudesonide/Glycopyr/Formoterol22$13,647

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$434$234,169224 claims
AstraZenecaFarxiga, Breztri Aerosphere$1,859$80,00299 claims
GSKTrelegy Ellipta, Breo Ellipta$1,199$74,764111 claims
PfizerEliquis$659$66,13686 claims
MerckJanuvia, Janumet$241$60,90662 claims
GileadBiktarvy$796$60,30914 claims
AbbVieUbrelvy, Vraylar, Synthroid$1,175$58,422108 claims
AmgenProlia$33,401$32,55819 claims
Boehringer IngelheimTradjenta, Jardiance, Pradaxa$152$29,33140 claims
Johnson & JohnsonXarelto$207$20,56927 claims
Novo NordiskOzempic$663$11,05312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in Asbury Park

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →